NanoBio Corporation
today announced compelling preclinical data for NB-201, a nanoemulsion-based
topical lotion for the treatment of burn wounds. In preclinical studies, NB-201
dramatically reduced the severity of burn wound infections as well as inflammation
following thermal injuries. The research was conducted at the University of
Michigan Medical School in Ann Arbor as a collaborative effort between the University
and NanoBio. The study results are being presented at the 2009 Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco,
Calif.
In the study, partial thickness burn wounds in rats were inoculated with Pseudomonas
aeruginosa bacteria, and then were treated 8 and 16 hours later with NB-201,
placebo, 5% Sulfamylon and a saline control. Treatment with NB-201 resulted
in a one-thousand fold reduction of bacterial growth as compared to control
(p<0.001). In addition, NB-201 demonstrated a greater reduction of bacterial
counts than Sulfamylon, a common topical antimicrobial currently used in the
treatment of burn injuries.
“NB-201 clearly demonstrated an ability to eradicate bacteria in a burn
wound. As importantly, it also resulted in reduction of proinflammatory cytokines
and local tissue inflammation which was coupled with a reduction in capillary
leak and local tissue edema,” said Mark R. Hemmila, MD Associate Professor
of Surgery at the University of Michigan Medical School. “NB-201 has the
potential to be very useful in helping prevent infection to the damaged area
of the wound and to reduce early post-burn inflammation.”
These findings indicate the potential benefits of NB-201 for treating burn
wounds, by both reducing bacterial growth and mitigating a local inflammatory
response which can lead to ongoing loss of intravascular fluid, systemic inflammation
and end-organ dysfunction. The underlying technology for NB-201 is NanoBio’s
NanoStat™ platform technology, which employs high-energy, oil-in-water
emulsion droplets that are manufactured at a size of 200-600 nanometers.